IDH1 and acute myeloid leukemia: Promisingly, ivosidenib (AG-120) has been approved by FDA as first-line treatment for acute myeloid leukemia (AML) with IDH1 mutation after a positive clinical trial (NCT02074839), further indicating the therapeutic potential of targeting this alteration.